Genistein enhances the efficacy of cabazitaxel chemotherapy in metastatic castration-resistant prostate cancer cells

Prostate

Volumn 73, Issue 15, 2013, Pages 1681-1689

  Zhang, Shumin ^a   Wang, Yanru ^a   Chen, Zhengjia ^b   Kim, Sungjin ^b   Iqbal, Shareen ^a   Chi, Andrew ^a   Ritenour, Chad ^a   Wang, Yongqiang A ^c   Kucuk, Omer ^a   Wu, Daqing ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c OCEAN NANOTECH LLC   (United States)

Author keywords

cabazitaxel; chemoresistance; experimental model; genistein; prostate cancer

Indexed keywords

CABAZITAXEL; GENISTEIN; LUCIFERASE; PROTEIN BAX; PROTEIN MCL 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CASTRATION RESISTANT PROSTATE CANCER; CELL VIABILITY; CHEMOSENSITIZATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; METASTASIS; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR XENOGRAFT;

CABAZITAXEL; CHEMORESISTANCE; EXPERIMENTAL MODEL; GENISTEIN; PROSTATE CANCER;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; CELL PROLIFERATION; GENISTEIN; HUMANS; MALE; MICE; MICE, NUDE; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROSTATE; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 84884904004     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22705     Document Type: Article

References (43)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin 2012; 62 (1): 10-29.
2. Huggins C, Hodges CV,. Studies on prostatic cancer: I. The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002; 168 (1): 9-12.
3. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA,. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351 (15): 1502-1512.
4. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED,. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351 (15): 1513-1520.
5. Pienta KJ, Smith DC,. Advances in prostate cancer chemotherapy: A new era begins. CA Cancer J Clin 2005; 55 (5): 300-318, quiz 305-323.
6. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO,. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010; 376 (9747): 1147-1154.
7. Seruga B, Ocana A, Tannock IF,. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 2011; 8 (1): 12-23.
8. Severson RK, Nomura AM, Grove JS, Stemmermann GN,. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res 1989; 49 (7): 1857-1860.
9. Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, Mack TM,. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 1991; 63 (6): 963-966.
10. Von Low EC, Perabo FG, Siener R, Muller SC,. Review. Facts and fiction of phytotherapy for prostate cancer: A critical assessment of preclinical and clinical data. In Vivo 2007; 21 (2): 189-204.
11. de Souza PL, Russell PJ, Kearsley JH, Howes LG,. Clinical pharmacology of isoflavones and its relevance for potential prevention of prostate cancer. Nutr Rev 2010; 68 (9): 542-555.
12. Jacobsen BK, Knutsen SF, Fraser GE,. Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Control 1998; 9 (6): 553-557.
13. Hwang YW, Kim SY, Jee SH, Kim YN, Nam CM,. Soy food consumption and risk of prostate cancer: A meta-analysis of observational studies. Nutr Cancer 2009; 61 (5): 598-606.
14. Carter MW, Smart WW Jr, Matrone G,. Estimation of estrogenic activity of genistein obtained from soybean meal. Proc Soc Exp Biol Med 1953; 84 (2): 506-508.
15. Li Y, Sarkar FH,. Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin Cancer Res 2002; 8 (7): 2369-2377.
16. Hussain M, Banerjee M, Sarkar FH, Djuric Z, Pollak MN, Doerge D, Fontana J, Chinni S, Davis J, Forman J, Wood DP, Kucuk O,. Soy isoflavones in the treatment of prostate cancer. Nutr Cancer 2003; 47 (2): 111-117.
17. Lazarevic B, Boezelijn G, Diep LM, Kvernrod K, Ogren O, Ramberg H, Moen A, Wessel N, Berg RE, Egge-Jacobsen W, Hammarstrom C, Svindland A, Kucuk O, Saatcioglu F, Tasken KA, Karlsen SJ,. Efficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: A randomized, placebo-controlled, double-blind Phase 2 clinical trial. Nutr Cancer 2011; 63 (6): 889-898.
18. Li Y, Kucuk O, Hussain M, Abrams J, Cher ML, Sarkar FH,. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. Cancer Res 2006; 66 (9): 4816-4825.
19. Xu L, Ding Y, Catalona WJ, Yang XJ, Anderson WF, Jovanovic B, Wellman K, Killmer J, Huang X, Scheidt KA, Montgomery RB, Bergan RC,. MEK4 function, genistein treatment, and invasion of human prostate cancer cells. J Natl Cancer Inst 2009; 101 (16): 1141-1155.
20. Lakshman M, Xu L, Ananthanarayanan V, Cooper J, Takimoto CH, Helenowski I, Pelling JC, Bergan RC,. Dietary genistein inhibits metastasis of human prostate cancer in mice. Cancer Res 2008; 68 (6): 2024-2032.
21. El Touny LH, Banerjee PP,. Identification of a biphasic role for genistein in the regulation of prostate cancer growth and metastasis. Cancer Res 2009; 69 (8): 3695-3703.
22. Ahmad IU, Forman JD, Sarkar FH, Hillman GG, Heath E, Vaishampayan U, Cher ML, Andic F, Rossi PJ, Kucuk O,. Soy isoflavones in conjunction with radiation therapy in patients with prostate cancer. Nutr Cancer 2010; 62 (7): 996-1000.
23. Davis JN, Kucuk O, Sarkar FH,. Genistein inhibits NF-kappa B activation in prostate cancer cells. Nutr Cancer 1999; 35 (2): 167-174.
24. Russo M, Spagnuolo C, Tedesco I, Russo GL,. Phytochemicals in cancer prevention and therapy: Truth or dare ? Toxins 2010; 2 (4): 517-551.
25. Lazarevic B, Hammarstrom C, Yang J, Ramberg H, Diep LM, Karlsen SJ, Kucuk O, Saatcioglu F, Tasken KA, Svindland A,. The effects of short-term genistein intervention on prostate biomarker expression in patients with localised prostate cancer before radical prostatectomy. Br J Nutr 2012; 108 (12): 2138-2147.
26. Messina M, Kucuk O, Lampe JW,. An overview of the health effects of isoflavones with an emphasis on prostate cancer risk and prostate-specific antigen levels. J AOAC Int 2006; 89 (4): 1121-1134.
27. Pavese JM, Farmer RL, Bergan RC,. Inhibition of cancer cell invasion and metastasis by genistein. Cancer Metastasis Rev 2010; 29 (3): 465-482.
28. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW,. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994; 54 (10): 2577-2581.
29. Xu J, Wang R, Xie ZH, Odero-Marah V, Pathak S, Multani A, Chung LW, Zhau HE,. Prostate cancer metastasis: Role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate 2006; 66 (15): 1664-1673.
30. Wu D, Zhau HE, Huang WC, Iqbal S, Habib FK, Sartor O, Cvitanovic L, Marshall FF, Xu Z, Chung LW,. cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: Implication in human prostate cancer bone metastasis. Oncogene 2007; 26 (35): 5070-5077.
31. Shin DM, Zhang H, Saba NF, Chen AY, Nannapaneni S, Amin AR, Muller S, Lewis M, Sica G, Kono S, Brandes JC, Grist WJ, Moreno-Williams R, Beitler JJ, Thomas SM, Chen Z, Shin HJ, Grandis JR, Khuri FR, Chen ZG,. Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: Preclinical and clinical studies. Clin Cancer Res 2013; 19 (5): 1244-1256.
32. Gleave M, Hsieh JT, Gao CA, von Eschenbach AC, Chung LW,. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 1991; 51 (14): 3753-3761.
33. Hsieh CL, Xie Z, Yu J, Martin WD, Datta MW, Wu GJ, Chung LW,. Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model. Prostate 2007; 67 (7): 685-691.
34. Seruga B, Tannock IF,. Chemotherapy-based treatment for castration-resistant prostate cancer. J Clin Oncol 2011; 29 (27): 3686-3694.
35. Keizman D, Maimon N, Gottfried M,. Metastatic hormone refractory prostate cancer: Recent advances in standard treatment paradigm, and future directions. Am J Clin Oncol 2012; (Epub ahead of print).
36. Kao SC, Hovey E, Marx G,. Second-line therapy for castrate-resistant prostate cancer: A literature review. Asia Pac J Clin Oncol 2011; 7 (3): 212-223.
37. Lheureux S, Joly F,. Cabazitaxel after docetaxel: A new option in metastatic castration-resistant prostate cancer. Bull Cancer 2012; 99 (9): 875-880.
38. Goetz D,. New options for the management of castration-resistant prostate cancer: A case perspective. J Natl Compr Canc Netw 2011; 9 (Suppl. 3): S13-S23, quiz S24.
39. Walensky LD, Gavathiotis E,. BAX unleashed: The biochemical transformation of an inactive cytosolic monomer into a toxic mitochondrial pore. Trends Biochem Sci 2011; 36 (12): 642-652.
40. Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW,. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci USA 1993; 90 (8): 3516-3520.
41. Raffoul JJ, Banerjee S, Che M, Knoll ZE, Doerge DR, Abrams J, Kucuk O, Sarkar FH, Hillman GG,. Soy isoflavones enhance radiotherapy in a metastatic prostate cancer model. Int J Cancer 2007; 120 (11): 2491-2498.
42. Zhao R, Xiang N, Domann FE, Zhong W,. Effects of selenite and genistein on G2/M cell cycle arrest and apoptosis in human prostate cancer cells. Nutr Cancer 2009; 61 (3): 397-407.
43. Tacyildiz N, Ozyoruk D, Yavuz G, Unal E, Dincaslan H, Dogu F, Sahin K, Kucuk O,. Soy isoflavones ameliorate the adverse effects of chemotherapy in children. Nutr Cancer 2010; 62 (7): 1001-1005.